A phase I, open-label, dose-escalation study to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of INCB024360 in patients with advanced malignancies

Trial Profile

A phase I, open-label, dose-escalation study to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of INCB024360 in patients with advanced malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jan 2017

At a glance

  • Drugs Epacadostat (Primary)
  • Indications Cancer
  • Focus Adverse reactions; First in man
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 04 Jan 2017 Results analysing safety, pharmacokinetics, pharmacodynamics and antitumor activity published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 19 Dec 2016 Results of population pharmacokinetic and pharmacodynamic modeling published in the Journal of Clinical Pharmacology
    • 03 Jun 2013 Final results were presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top